Lindis Blood Care GmbH

Lindis Blood Care GmbH is a startup based in Germany.

Lindis Blood Care GmbH is a German MedTech company that developed CATUVAB®, a medical device using Antibody-Based Cell Removal Technology (ABCR-T) to aggregate and remove tumor and immune cells from salvaged blood to enable safer intraoperative autologous blood transfusions in cancer surgeries. Founded in 2018, the company has completed a multicenter clinical REMOVE study and is preparing regulatory launches (EU launch expected Q4 2025; FDA submission noted).